Categories Technology

Apple may launch three iPhones with 7nm chip this year

Apple’s (AAPL) upcoming iPhone models this year would have an A12 chip with 7-nanometer design instead of the current 10-nanometer chips, which features in iPhone 8 and iPhone X. In addition, Apple is widely expected to launch three new iPhones this year.

Apple iPhone X black
Picture Courtesy: Apple

The new 7-nanometer A12 chipset, which is already under production by Apple’s manufacturing partner Taiwan Semiconductor Manufacturing Co or TSMC, will be smaller, faster and more efficient than the current chipset, according to the Bloomberg. The market is expecting the A12 chip to come with 2.6 or 2.8 GHz octa-core CPU processor and Apple Custom GPU. The 7-nanometer technology specifies the density of transistors on a chip.

The neural engine hardware is used for Face ID, Animoji, and other machine-learning tasks. The A11 Bionic chipset is much faster than the A10 Fusion, which appeared in the 10.5-inch iPad Pro and the second generation of 12.9-inch iPad Pro.

Besides these, Apple is also expected to launch an update to the iPhone X, a plus-size variant, and a lower-cost LCD device. The company will likely introduce these devices this fall.

Apple is widely expected to launch three new iPhones with a 7-nanometer chip this year.

Speculations are rife that the next iPhone might have hand gesture control as well as a curved screen. However, a Bloomberg report showed that the curved screen and controlled gestures could take several months to come in the iPhones. Already Samsung Galaxy premium models have curved screens and air gesture feature.

Meanwhile, Apple has sent out a press invitation for Worldwide Developer Conference 2018, which runs from June 4 to 8, with developer sessions on the company’s latest platform technology. The company is expected to make a slew of announcements on the opening day, including iOS12, macOS 10.14, tvOS 12, watchOS 5 and possible improvements to Siri and HomePod.

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top